Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: New Visitation Guidelines. Click here for what to expect at ChristianaCare during COVID-19.

Breast Cancer Research Program at the
Helen F. Graham Cancer Center
& Research Institute

Community Research Advisory Board

ChristianaCare’s Community Research Advisory Board brings together breast cancer survivors, community leaders and health care experts to advance scientific discovery. Members bring their unique perspective to the table to identify issues of critical importance to our community for translational cancer research teams at the Helen F. Graham Cancer Center, and build networks throughout our community to educate neighbors about cancer risk assessment, prevention, early detection, treatment options and clinical research trials.

One of the first challenges identified by the Community Research Advisory Board is Delaware’s very high incidence of Triple Negative Breast Cancer, especially among African-American women.

To help community health ambassadors educate women about this aggressive form of breast cancer, they created The Story of BRENDA — a free community education program. The acronym BRENDA helps women remember key steps they can take to reduce their risk for Triple Negative Breast Cancer:

Breastfeed
Reduce alcohol
Exercise
Nutritious foods
Don’t smoke
Achieve a healthy body weight

Call 302-623-4661 or complete the request form to schedule a speaker today for your faith, professional or community group!

If you would like to be part of the Community Research Advisory Board to promote education and awareness in our community about breast cancer health and research, contact us at translationalresearch@christianacare.org. Members are asked to participate in up to three in-person evening meetings per year.

Cancer Research Program
Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Suite 2200, Newark, DE 19713 directions
For more information, call 302-623-4450 or e-mail us.